Rigel Pharmaceuticals price target lowered to $1.25 from $1.75 at B. Riley

B. Riley lowered the firm’s price target on Rigel Pharmaceuticals to $1.25 from $1.75 and keeps a Neutral rating on the shares. The company’s Q3 update was highlighted by growing Tavalisse sales, as Rigel delivered the highest total number of bottles sold in the U.S. during the quarter, the analyst tells investors in a research note. However, revised assumptions for Rezlidhia drove the target drop.